Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00788099 · ClinicalTrials.gov registry record · Phase 1

Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas

A Phase 1 study of Advanced Solid Tumors and Lymphomas, sponsored by PharmaMar.

Completed
Registry status
Phase 1
Development phase
45
Enrollment target
2
Study locations

NCT00788099 is a Phase 1 study of Advanced Solid Tumors and Lymphomas that has completed, run by PharmaMar. The registered enrollment target is 45 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (77% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00788099, a Phase 1 study of Advanced Solid Tumors and Lymphomas, has completed, sponsored by PharmaMar.

COMPLETED
Registry status
Phase 1
Development phase
45 participants
Enrollment target
2
Study locations

Study Summary

Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Plitidepsin in Combination with Sorafenib or Gemcitabine in Patients with Advanced Solid Tumors or Lymphomas to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of plitidepsin in combination with sorafenib or gemcitabine in patients with advanced solid tumors or lymphomas.

Conditions Studied

Advanced Solid Tumors Lymphomas

Interventions

  • DRUG Plitidepsin and Sorafenib
  • DRUG Gemcitabine and Plitidepsin

Study Locations (2)

New Jersey

  • The Cancer Institute of New Jersey (CINJ) - New Brunswick

Other

  • Institut Gustave Roussy - Villejuif

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2008-12
Est. Completion 2011-06
Phase Phase 1

Sponsor

PharmaMar

32 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00788099

The ClinicalTrials.gov registry entry for NCT00788099 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (77% lower). The listed sponsor is PharmaMar, which has 32 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Plitidepsin and Sorafenib is the first listed.

NCT00788099 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New Jersey, Other.

Frequently Asked Questions

What is clinical trial NCT00788099 about?

NCT00788099 is a clinical study titled "Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas". Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Plitidepsin in Combination with Sorafenib or Gemcitabine in Patients with Advanced Solid Tumors or Lymphomas to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of plitidepsin in combination with sorafenib...

What is the current status of trial NCT00788099?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2008-12. Estimated completion is 2011-06.

What conditions does trial NCT00788099 study?

This clinical trial studies the following conditions: Advanced Solid Tumors, Lymphomas.

What interventions are being tested in trial NCT00788099?

The interventions under investigation include: Plitidepsin and Sorafenib (DRUG), Gemcitabine and Plitidepsin (DRUG).

Who is sponsoring clinical trial NCT00788099?

This trial is sponsored by PharmaMar, which has 32 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00788099 being conducted?

This trial has 2 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

Lymphomas

All registered trials for this condition

New Jersey

All trials with a study site in New Jersey

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.